{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T05:37:08Z","timestamp":1765949828871,"version":"3.48.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T00:00:00Z","timestamp":1762732800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T00:00:00Z","timestamp":1762732800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s00520-025-10103-w","type":"journal-article","created":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T07:39:09Z","timestamp":1762760349000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Otoprotective measures for cisplatin-based chemoradiotherapy-induced toxicity in patients with head and neck cancer: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3652-9486","authenticated-orcid":false,"given":"Katia Regina","family":"Marchetti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1032-6405","authenticated-orcid":false,"given":"Leonardo Duarte","family":"Guerra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-2752-9718","authenticated-orcid":false,"given":"Pedro Angelo Luzini","family":"Gondim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8765-3044","authenticated-orcid":false,"given":"Gilberto","family":"de Castro Junior","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,10]]},"reference":[{"key":"10103_CR1","unstructured":"World Health Organization (2022) Cancer today. [Internet] Accessed 14 May 2024. https:\/\/gco.iarc.who.int\/today\/"},{"key":"10103_CR2","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1245\/s10434-010-0985-4","volume":"17","author":"SB Edge","year":"2010","unstructured":"Edge SB, Compton CC (2010) The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 17:1471\u20131474. https:\/\/doi.org\/10.1245\/s10434-010-0985-4","journal-title":"Ann Surg Oncol"},{"key":"10103_CR3","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.radonc.2021.01.013","volume":"156","author":"B Lacas","year":"2021","unstructured":"Lacas B, Carmel A, Landais C et al (2021) Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC group. Radiother Oncol 156:281\u2013293. https:\/\/doi.org\/10.1016\/j.radonc.2021.01.013","journal-title":"Radiother Oncol"},{"key":"10103_CR4","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1007\/s10162-008-0126-y","volume":"9","author":"H So","year":"2008","unstructured":"So H, Kim H, Kim Y, Kim E, Pae HO, Chung HT, Kim HJ, Kwon KB, Lee KM, Lee HY, Moon SK, Park R (2008) Evidence that cisplatin-induced auditory damage is attenuated by downregulation of pro-inflammatory cytokines via Nrf2\/HO-1. J Assoc Res Otolaryngol 9:290\u2013306. https:\/\/doi.org\/10.1007\/s10162-008-0126-y","journal-title":"J Assoc Res Otolaryngol"},{"key":"10103_CR5","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1097\/MOO.0b013e3282eee452","volume":"15","author":"LP Rybak","year":"2007","unstructured":"Rybak LP (2007) Mechanisms of cisplatin ototoxicity and progress in otoprotection. Curr Opin Otolaryngol Head Neck Surg 15:364\u2013369. https:\/\/doi.org\/10.1097\/MOO.0b013e3282eee452","journal-title":"Curr Opin Otolaryngol Head Neck Surg"},{"key":"10103_CR6","unstructured":"Rivelli TG, Mak MP, Martins RE, da Costa e Silva VT, de Castro G Jr (2015) Cisplatin based chemoradiation late toxicities in head and neck squamous cell carcinoma patients. Discov Med 20:57\u201366"},{"key":"10103_CR7","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"D Moher","year":"2021","unstructured":"Moher D, Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71. https:\/\/doi.org\/10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"10103_CR8","unstructured":"DeCS [Internet]. 2024 ed. S\u00e3o Paulo (SP): BIREME \/ PAHO \/ WHO. 2024 [updated 8 February 2024]. Accessed 14 May 2024. https:\/\/decs.bvsalud.org\/en\/"},{"key":"10103_CR9","first-page":"477","volume":"94","author":"P Blobaum","year":"2006","unstructured":"Blobaum P (2006) Physiotherapy Evidence Database (PEDro). J Med Libr Assoc 94:477\u2013478","journal-title":"J Med Libr Assoc"},{"key":"10103_CR10","doi-asserted-by":"publisher","unstructured":"Yi Y, Lin A, Zhou C, Jian Z, Wang S, Luo P (2022) Onlinemeta: a web server for meta-analysis based on R-shiny. bioRxiv:2022.2004.2013.488126. https:\/\/doi.org\/10.1101\/2022.04.13.488126","DOI":"10.1101\/2022.04.13.488126"},{"key":"10103_CR11","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/s1053-4296(03)00031-6","volume":"13","author":"A Trotti","year":"2003","unstructured":"Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, Langer C, Murphy B, Cumberlin R, Coleman CN, Rubin P (2003) CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 13:176\u2013181. https:\/\/doi.org\/10.1016\/s1053-4296(03)00031-6","journal-title":"Semin Radiat Oncol"},{"key":"10103_CR12","unstructured":"National Cancer Institute (2009) Common terminology criteria for adverse events (CTCAE) v4.0. U.S. Department of Health and Human Services, National Institutes of Health. https:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03\/Archive\/CTCAE_4.0_2009-05-29_QuickReference_8.5x11.pdf"},{"key":"10103_CR13","doi-asserted-by":"crossref","unstructured":"Kiyota N, Tahara M, Mizusawa J, Kodaira T, Fujii H, Yamazaki T et al (2022) Weekly cisplatin plus radiation for postoperative head and neck cancer (JCOG1008): a multicenter, noninferiority, phase II\/III Randomized controlled trial. J Clin Oncol 40(18):1980\u201390","DOI":"10.1200\/JCO.21.01293"},{"issue":"1","key":"10103_CR14","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.ijrobp.2024.07.2315","volume":"121","author":"V Noronha","year":"2025","unstructured":"Noronha V, Patil V, Menon N, Singh A, Shah M, Shetake A, Peelay Z, Mathrudev V, Nawale K, Shah S, Prabhash K (2025Jan 1) Long-Term Update of a Phase 3 Randomized Study Comparing Once-a-Week Versus Once-Every-3-Weeks Cisplatin Along With Radiation in Head and Neck Cancer. Int J Radiat Oncol Biol Phys 121(1):128\u2013136","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10103_CR15","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1002\/cam4.2072","volume":"8","author":"MB Visacri","year":"2019","unstructured":"Visacri MB, Quintanilha JCF, de Sousa VM et al (2019) Can acetylcysteine ameliorate cisplatin-induced toxicities and oxidative stress without decreasing antitumor efficacy? A randomized, double-blind, placebo-controlled trial involving patients with head and neck cancer. Cancer Med 8:2020\u20132030. https:\/\/doi.org\/10.1002\/cam4.2072","journal-title":"Cancer Med"},{"key":"10103_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s40463-019-0327-x","volume":"48","author":"V Rolland","year":"2019","unstructured":"Rolland V, Meyer F, Guitton JM, Bussi\u00e8res R, Philippon D, Bairati I, Leclerc M, C\u00f4t\u00e9 M (2019) A randomized controlled trial to test the efficacy of trans-tympanic injections of a sodium thiosulfate gel to prevent cisplatin-induced ototoxicity in patients with head and neck cancer. J Otolaryngol Head Neck Surg 48:4. https:\/\/doi.org\/10.1186\/s40463-019-0327-x","journal-title":"J Otolaryngol Head Neck Surg"},{"key":"10103_CR17","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/s1470-2045(18)30104-9","volume":"19","author":"LQ Tang","year":"2018","unstructured":"Tang LQ, Chen DP, Guo L et al (2018) Concurrent chemoradiotherapy with nedaplatin versus cisplatin in stage II-IVB nasopharyngeal carcinoma: an open-label, non-inferiority, randomised phase 3 trial. Lancet Oncol 19:461\u2013473. https:\/\/doi.org\/10.1016\/s1470-2045(18)30104-9","journal-title":"Lancet Oncol"},{"key":"10103_CR18","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1093\/jnci\/djy133","volume":"111","author":"JM Bauml","year":"2019","unstructured":"Bauml JM, Vinnakota R, Anna Park YH et al (2019) Cisplatin every 3 weeks versus weekly with definitive concurrent radiotherapy for squamous cell carcinoma of the head and neck. J Natl Cancer Inst 111:490\u2013497. https:\/\/doi.org\/10.1093\/jnci\/djy133","journal-title":"J Natl Cancer Inst"},{"key":"10103_CR19","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.44299","volume":"15","author":"D Gupta","year":"2023","unstructured":"Gupta D, Singh G, Garg P, Dey R, Singh B (2023) Intratympanic dexamethasone role in hearing protection in cancer patients. Cureus 15:e44299. https:\/\/doi.org\/10.7759\/cureus.44299","journal-title":"Cureus"},{"key":"10103_CR20","doi-asserted-by":"publisher","first-page":"3759","DOI":"10.1200\/jco.2006.08.9540","volume":"25","author":"CL Zuur","year":"2007","unstructured":"Zuur CL, Simis YJ, Lansdaal PE, Hart AA, Schornagel JH, Dreschler WA, Rasch CR, Balm AJ (2007) Ototoxicity in a randomized phase III trial of intra-arterial compared with intravenous cisplatin chemoradiation in patients with locally advanced head and neck cancer. J Clin Oncol 25:3759\u20133765. https:\/\/doi.org\/10.1200\/jco.2006.08.9540","journal-title":"J Clin Oncol"},{"key":"10103_CR21","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.oraloncology.2016.06.004","volume":"59","author":"D Rades","year":"2016","unstructured":"Rades D, Seidl D, Janssen S, Bajrovic A, Hakim SG, Wollenberg B, Karner K, Strojan P, Schild SE (2016) Chemoradiation of locally advanced squamous cell carcinoma of the head-and-neck (LASCCHN): is 20mg\/m(2) cisplatin on five days every four weeks an alternative to 100mg\/m(2) cisplatin every three weeks? Oral Oncol 59:67\u201372. https:\/\/doi.org\/10.1016\/j.oraloncology.2016.06.004","journal-title":"Oral Oncol"},{"key":"10103_CR22","doi-asserted-by":"publisher","first-page":"2720","DOI":"10.1002\/lary.24802","volume":"124","author":"EA Theunissen","year":"2014","unstructured":"Theunissen EA, Zuur CL, Bosma SC, Lopez-Yurda M, Hauptmann M, van der Baan S, de Boer JP, van der Molen L, Rasch CR, Dreschler WA, Balm AJ (2014) Long-term hearing loss after chemoradiation in patients with head and neck cancer. Laryngoscope 124:2720\u20132725. https:\/\/doi.org\/10.1002\/lary.24802","journal-title":"Laryngoscope"},{"key":"10103_CR23","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.oraloncology.2018.12.010","volume":"89","author":"WA Teft","year":"2019","unstructured":"Teft WA, Winquist E, Nichols AC et al (2019) Predictors of cisplatin-induced ototoxicity and survival in chemoradiation treated head and neck cancer patients. Oral Oncol 89:72\u201378. https:\/\/doi.org\/10.1016\/j.oraloncology.2018.12.010","journal-title":"Oral Oncol"},{"key":"10103_CR24","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1007\/s00405-015-3857-5","volume":"273","author":"R Niemensivu","year":"2016","unstructured":"Niemensivu R, Saarilahti K, Ylikoski J, Aarnisalo A, M\u00e4kitie AA (2016) Hearing and tinnitus in head and neck cancer patients after chemoradiotherapy. Eur Arch Otorhinolaryngol 273:2509\u20132514. https:\/\/doi.org\/10.1007\/s00405-015-3857-5","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"10103_CR25","doi-asserted-by":"publisher","first-page":"919","DOI":"10.3109\/00016489.2015.1035797","volume":"135","author":"E Ishikawa","year":"2015","unstructured":"Ishikawa E, Sugimoto H, Hatano M, Nakanishi Y, Tsuji A, Endo K, Kondo S, Wakisaka N, Murono S, Ito M, Yoshizaki T (2015) Protective effects of sodium thiosulfate for cisplatin-mediated ototoxicity in patients with head and neck cancer. Acta Otolaryngol 135:919\u2013924. https:\/\/doi.org\/10.3109\/00016489.2015.1035797","journal-title":"Acta Otolaryngol"},{"key":"10103_CR26","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1001\/archotol.1996.01890140029007","volume":"122","author":"CW Newman","year":"1996","unstructured":"Newman CW, Jacobson GP, Spitzer JB (1996) Development of the tinnitus handicap inventory. Arch Otolaryngol Head Neck Surg 122:143\u2013148. https:\/\/doi.org\/10.1001\/archotol.1996.01890140029007","journal-title":"Arch Otolaryngol Head Neck Surg"},{"key":"10103_CR27","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1590\/s1808-86942010000400019","volume":"76","author":"AH Dell'Aringa","year":"2010","unstructured":"Dell\u2019Aringa AH, Isaac Mde L, Arruda GV, Dell\u2019Aringa AR, Esteves MC (2010) Audiological findings in patients treated with radiotherapy for head and neck tumors. Braz J Otorhinolaryngol 76:527\u2013532. https:\/\/doi.org\/10.1590\/s1808-86942010000400019","journal-title":"Braz J Otorhinolaryngol"},{"key":"10103_CR28","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1001\/jamaoto.2015.1515","volume":"141","author":"EA Theunissen","year":"2015","unstructured":"Theunissen EA, Zuur CL, J\u00f3zwiak K, Lopez-Yurda M, Hauptmann M, Rasch CR, van der Baan S, de Boer JP, Dreschler WA, Balm AJ (2015) Prediction of hearing loss due to cisplatin chemoradiotherapy. JAMA Otolaryngol Head Neck Surg 141:810\u2013815. https:\/\/doi.org\/10.1001\/jamaoto.2015.1515","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"key":"10103_CR29","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15061759","volume":"15","author":"LT Macedo","year":"2023","unstructured":"Macedo LT, Costa EFD, Carvalho BF, Louren\u00e7o GJ, Calonga L, Castilho AM, Chone CT, Lima CSP (2023) Association of clinical aspects and genetic variants with the severity of cisplatin-induced ototoxicity in head and neck squamous cell carcinoma: a prospective cohort study. Cancers (Basel) 15:1759. https:\/\/doi.org\/10.3390\/cancers15061759","journal-title":"Cancers (Basel)"},{"key":"10103_CR30","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1016\/j.ijrobp.2007.01.042","volume":"68","author":"CL Zuur","year":"2007","unstructured":"Zuur CL, Simis YJ, Lansdaal PE, Hart AA, Rasch CR, Schornagel JH, Dreschler WA, Balm AJ (2007) Risk factors of ototoxicity after cisplatin-based chemo-irradiation in patients with locally advanced head-and-neck cancer: a multivariate analysis. Int J Radiat Oncol Biol Phys 68:1320\u20131325. https:\/\/doi.org\/10.1016\/j.ijrobp.2007.01.042","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10103_CR31","volume-title":"Cisplatin product monograph","author":"Mayne Pharma Inc","year":"2003","unstructured":"Mayne Pharma Inc (2003) Cisplatin product monograph. Mayne Pharma Inc., Montreal, Canada"},{"key":"10103_CR32","doi-asserted-by":"crossref","unstructured":"Kim JK, Leeman JE, Riaz N, McBride S, Tsai CJ, Lee NY (2018) Proton therapy for head and neck cancer. Curr Treat Options Oncol 19(6):28","DOI":"10.1007\/s11864-018-0546-9"},{"key":"10103_CR33","doi-asserted-by":"crossref","unstructured":"Nuyts S, Bollen H, Ng SP, Corry J, Eisbruch A, Mendenhall WM et al (2022) Proton therapy for squamous cell carcinoma of the head and neck: early clinical experience and current challenges. Cancers (Basel) 14(11):2587","DOI":"10.3390\/cancers14112587"},{"key":"10103_CR34","doi-asserted-by":"crossref","unstructured":"Frank SJ, Busse P, Rosenthal DI, Hernandez M, Swanson DM, Garden AS et al (2024) Phase III randomized trial of intensity-modulated proton therapy (IMPT) versus intensity-modulated photon therapy (IMRT) for the treatment of head and neck oropharyngeal carcinoma (OPC). JCO 42(16_suppl):6006\u20136006","DOI":"10.1200\/JCO.2024.42.16_suppl.6006"},{"key":"10103_CR35","doi-asserted-by":"crossref","unstructured":"Sun L, Candelieri-Surette D, Anglin-Foote T, Lynch JA, Maxwell KN, D\u2019Avella C et al (2022) Cetuximab-based vs carboplatin-based chemoradiotherapy for patients with head and neck cancer. JAMA Otolaryngol Head Neck Surg 148(11):1022\u20138","DOI":"10.1001\/jamaoto.2022.2791"},{"key":"10103_CR36","doi-asserted-by":"crossref","unstructured":"Corry J, Bressel M, Fua T, Herschtal A, Solomon B, Porceddu SV et al (2017) Prospective study of cetuximab, carboplatin, and radiation therapy for patients with locally advanced head and neck squamous cell cancer unfit for cisplatin. Int J Radiat Oncol Biol Phys de98(4):948\u201354","DOI":"10.1016\/j.ijrobp.2017.02.088"},{"key":"10103_CR37","doi-asserted-by":"publisher","unstructured":"Hamauchi S, Yokota T, Onozawa Y, Ogawa H, Onoe T, Kamijo T et al (2015) Safety and efficacy of concurrent carboplatin plus radiotherapy for locally advanced head and neck cancer patients ineligible for treatment with cisplatin. Jpn J Clin Oncol 45(12):1116\u201321. https:\/\/doi.org\/10.1093\/jjco\/hyv142","DOI":"10.1093\/jjco\/hyv142"},{"issue":"2","key":"10103_CR38","doi-asserted-by":"publisher","first-page":"453","DOI":"10.4103\/ijc.IJC_320_17","volume":"54","author":"V Noronha","year":"2017","unstructured":"Noronha V, Sharma V, Joshi A, Patil VM, Laskar SG, Prabhash K (2017) Carboplatin-based concurrent chemoradiation therapy in locally advanced head and neck cancer patients who are unfit for cisplatin therapy. Indian J Cancer 54(2):453\u2013457","journal-title":"Indian J Cancer"},{"key":"10103_CR39","doi-asserted-by":"crossref","unstructured":"Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB et al (2006) Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck.\u00a0N Engl\u00a0J Med 354(6):567\u201378","DOI":"10.1056\/NEJMoa053422"},{"key":"10103_CR40","doi-asserted-by":"crossref","unstructured":"Patil VM, Noronha V, Menon N, Singh A, Ghosh-Laskar S, Budrukkar A et al (2023) Results of phase iii randomized trial for use of docetaxel as a radiosensitizer in patients with head and neck cancer, unsuitable for cisplatin-based chemoradiation. J Clin Oncol 41(13):2350\u201361","DOI":"10.1200\/JCO.22.00980"},{"issue":"22","key":"10103_CR41","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.2217\/fon-2022-1146","volume":"19","author":"RT Hughes","year":"2023","unstructured":"Hughes RT, Gebeyehu RR, Kalada JM, Lycan TW, Frizzell BA, Kinney RD et al (2023) Quad-shot-immunotherapy: quad-shot radiotherapy with pembrolizumab for advanced\/recurrent head and neck cancer. Future Oncol julho de 19(22):1523\u20131534","journal-title":"Future Oncol julho de"},{"key":"10103_CR42","doi-asserted-by":"crossref","unstructured":"Tao Y, Biau J, Sun XS, Sire C, Martin L, Alfonsi M et al (2023) Pembrolizumab versus cetuximab concurrent with radiotherapy in patients with locally advanced squamous cell carcinoma of head and neck unfit for cisplatin (GORTEC 2015\u201301 PembroRad): a multicenter, randomized, phase II trial. Ann Oncol 34(1):101\u201310","DOI":"10.1016\/j.annonc.2022.10.006"},{"key":"10103_CR43","doi-asserted-by":"crossref","unstructured":"Bera A, Banerjee C, Dutta S, Biswas L. Concurrent chemoradiation with paclitaxel in locally advanced head and neck cancer: A feasibility study from tertiary cancer care center. 2019 [Accessed 25 August 2024]; http:\/\/imsear.searo.who.int\/handle\/123456789\/205579","DOI":"10.5455\/ijmsph.2019.1028206102019"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-025-10103-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-025-10103-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-025-10103-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T05:32:37Z","timestamp":1765949557000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-025-10103-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,10]]},"references-count":43,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10103"],"URL":"https:\/\/doi.org\/10.1007\/s00520-025-10103-w","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"type":"print","value":"0941-4355"},{"type":"electronic","value":"1433-7339"}],"subject":[],"published":{"date-parts":[[2025,11,10]]},"assertion":[{"value":"26 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Our systematic review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) protocol and the\u00a0International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH) Guideline for Good Clinical Practice (GCP).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"As this is a systematic review, the patient informed consent form was unnecessary.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The images in Fig.\u00a0\n                      \n                      were made by the author.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1034"}}